While the impact of DM could lead to similar cardiovascular risks between the two treatment groups, the subgroup-specific effects and borderline significant interaction effect may suggest that DM affects the observed associations between enzalutamide use and risks of 4P-MACE.
← all excerpts
Major adverse cardiovascular events of enzalutamide versus abiraterone in prostate cancer: a retrospective cohort study.
1
—
—